Colonoscopy screening outcomes in Lynch syndrome and differential colorectal cancer paths among MLH1 / MSH2 carriers

Clicks: 12
ID: 332966
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #384 of 408 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUD: Lynch syndrome, caused by pathogenic variants in mismatch repair genes increases the risk of colorectal cancer, which remains elevated even under active colonoscopy surveillance. A deeper understanding of the underlying mechanisms driving CRC development under colonoscopy surveillance in individuals with LS is crucial for evaluating its effectiveness. The goal of this study is to better understand the differential patterns of CRC development focusing more specifically on MLH1 and MSH2 carriers. METHODS: Patients with Lynch syndrome were identified through the Familial Gastrointestinal Cancer Registry in the Zane Cohen Centre at Mount Sinai hospital, Toronto. This study proposed a general model integrating colonoscopy screening visits, adenoma counts, and CRC occurrence (a joint model) and which accounts for their interdependencies when modelling CRC risk. RESULTS: More frequent colonoscopy screenings resulting in an increased number of adenomas detected effectively reduces CRC risk in those with a pathogenic variant in MSH2, potentially due to a risk-reducing effect. MLH1 carriers did not experience the same benefit. After 10-year follow-up, among individuals with adenomas, CRC risk was much higher in MLH1 compared to MSH2 carriers, 7.9% [95% CI = 3.9-15.8%] vs. 4.0% [95% CI = 1.6-9.6%] in males and 4.2% [95% CI = 2.2-8.2%] vs. 1.6% [95% CI = 0.7-3.5%] in females. CONCLUSIONS: Our study identified differences in MLH1 and MSH2 cancer development which may suggest distinct mechanisms impacting CRC. The inverse relationship between adenoma detection and CRC risk in MSH2 carriers enhances our understanding of the adenoma-carcinoma sequence, while the lack of association in MLH1 carriers suggests alternative carcinogenic pathways requiring further study.
Reference Key
openalex_W7222974735 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Laurent Briollais, Yunhee Choi, Kara Semotiuk, Thomas Ward, Zane Cohen, Melyssa D. Aronson
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag392
URL
https://doi.org/10.1093/jnci/djag392
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.